Brent Standridge
2017
In 2017, Brent Standridge earned a total compensation of $614.9K as Chief Operating Officer at Aratana Therapeutics, a 41% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $81,300 |
|---|---|
| Option Awards | $106,209 |
| Salary | $307,500 |
| Stock Awards | $109,072 |
| Other | $10,800 |
| Total | $614,881 |
Standridge received $307.5K in salary, accounting for 50% of the total pay in 2017.
Standridge also received $81.3K in non-equity incentive plan, $106.2K in option awards, $109.1K in stock awards and $10.8K in other compensation.
Rankings
In 2017, Brent Standridge's compensation ranked 11,097th out of 14,666 executives tracked by ExecPay. In other words, Standridge earned more than 24.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 11,097 out of 14,666 | 24th |
Division Manufacturing | 4,336 out of 5,768 | 25th |
Major group Chemicals And Allied Products | 1,568 out of 2,074 | 24th |
Industry group Drugs | 1,288 out of 1,730 | 26th |
Industry Pharmaceutical Preparations | 1,003 out of 1,329 | 25th |
Source: SEC filing on June 8, 2018.
Standridge's colleagues
We found three more compensation records of executives who worked with Brent Standridge at Aratana Therapeutics in 2017.